Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
| 40 | |
| 40 | |
| - | |
| 40 | |
| 40 | |
| 29.6-48.8 | |
| 1 961 M | |
| 4000 | |
| 49 030 K | |
| 215 M | |
| -0.08 | |
| 1.674 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Total Revenue: $52.7 million for the second quarter. MACI Revenue: $44.1 million, a 21% increase year-over-year. Burn Care Revenue: $8.5 million, including Epicel revenue of $7.8 million and NexoBrid ...
As global markets navigate the complexities of escalating Middle East tensions and robust U.S. job growth, investors are closely monitoring the performance of key indices like the S&P 500 and Nasdaq C...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
